New research on commonly prescribed blood thinners shows that rivaroxaban, known better by its brand name Xarelto, was associated with a significantly higher risk of bleeding complications. To provide much-needed transparency for patients, U-M researchers tested three popular medications prescribed to treat blood clots or atrial fibrillation. Read about their findings in this article from the Institute for Healthcare Policy and Innovation.
